

Mohamad E Allaf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8776333/publications.pdf>

Version: 2024-02-01

126
papers

4,260
citations

147566

31
h-index

123241

61
g-index

127
all docs

127
docs citations

127
times ranked

6091
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.	6.0	898
2	ANATOMICAL EXTENT OF LYMPH NODE DISSECTION: IMPACT ON MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2004, 172, 1840-1844.	0.2	313
3	Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2117-2136.	3.3	234
4	Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. <i>Annals of Nuclear Medicine</i> , 2015, 29, 877-882.	1.2	152
5	Prospective Evaluation of 99mTc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. <i>European Urology</i> , 2016, 69, 413-416.	0.9	121
6	Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. <i>Journal of Nuclear Medicine</i> , 2018, 59, 871-877.	2.8	115
7	Grade Heterogeneity in Small Renal Masses: Potential Implications for Renal Mass Biopsy. <i>Journal of Urology</i> , 2015, 193, 36-40.	0.2	105
8	Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States. <i>European Urology Oncology</i> , 2019, 2, 343-348.	2.6	95
9	Prostate Specific Membrane Antigen Targeted ¹⁸ F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. <i>Journal of Urology</i> , 2018, 199, 126-132.	0.2	86
10	Safety and Early Oncologic Effectiveness of Primary Robotic Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer. <i>European Urology</i> , 2017, 71, 476-482.	0.9	85
11	Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. <i>Nature Reviews Urology</i> , 2017, 14, 90-97.	1.9	78
12	Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. <i>BJU International</i> , 2017, 119, 661-666.	1.3	71
13	Initial Experience Performing In-office Ultrasound-guided Transperineal Prostate Biopsy Under Local Anesthesia Using the PrecisionPoint Transperineal Access System. <i>Urology</i> , 2018, 115, 8-13.	0.5	65
14	Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study. <i>BJU International</i> , 2019, 123, 42-50.	1.3	65
15	Prospective Evaluation of PSMA-Targeted ¹⁸ F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 58-61.	2.8	61
16	A Prospective, Comparative Study of Quality of Life among Patients with Small Renal Masses Choosing Active Surveillance and Primary Intervention. <i>Journal of Urology</i> , 2016, 196, 1356-1362.	0.2	51
17	A comparative analysis of robotic vs laparoscopic retroperitoneal lymph node dissection for testicular cancer. <i>BJU International</i> , 2015, 116, 920-923.	1.3	50
18	International Consultation on Urological Diseases and European Association of Urology International Consultation on Minimally Invasive Surgery in Urology: laparoscopic and robotic adrenalectomy. <i>BJU International</i> , 2017, 119, 13-21.	1.3	49

#	ARTICLE	IF	CITATIONS
19	Partial vs Radical Nephrectomy for T1-T2 Renal Masses in the Elderly: Comparison of Complications, Renal Function, and Oncologic Outcomes. <i>Urology</i> , 2017, 100, 151-157.	0.5	49
20	[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 56471-56479.	0.8	49
21	A Prospective Cohort Study of Postdischarge Opioid Practices After Radical Prostatectomy: The ORIOLES Initiative. <i>European Urology</i> , 2019, 75, 215-218.	0.9	48
22	Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT. <i>Molecular Imaging and Biology</i> , 2019, 21, 567-573.	1.3	46
23	Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor. <i>Oncotarget</i> , 2015, 6, 33733-33742.	0.8	44
24	PSMA-Targeted 18F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy. <i>European Urology</i> , 2017, 71, 145-146.	0.9	40
25	Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. <i>Annals of Nuclear Medicine</i> , 2019, 33, 617-623.	1.2	40
26	Transperineal prostate biopsy with cognitive magnetic resonance imaging/biplanar ultrasound fusion: description of technique and early results. <i>World Journal of Urology</i> , 2020, 38, 1943-1949.	1.2	39
27	Semiquantitative Parameters in PSMA-Targeted PET Imaging with ¹⁸ F-DCFPyL: Variability in Normal-Organ Uptake. <i>Journal of Nuclear Medicine</i> , 2017, 58, 942-946.	2.8	38
28	Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: A multi-institutional analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 112.e9-112.e14.	0.8	36
29	Pathological characteristics and radiographic correlates of complex renal cysts. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1010-1016.	0.8	35
30	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , 2019, 15, 1683-1695.	1.1	35
31	Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia. <i>Annals of Nuclear Medicine</i> , 2017, 31, 696-702.	1.2	34
32	Correlation of 99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression. <i>EJNMMI Research</i> , 2017, 7, 80.	1.1	33
33	Active Surveillance is Superior to Radical Nephrectomy and Equivalent to Partial Nephrectomy for Preserving Renal Function in Patients with Small Renal Masses: Results from the DISSRM Registry. <i>Journal of Urology</i> , 2015, 194, 903-909.	0.2	32
34	Consumer Preferences and Online Comparison Tools Used to Select a Surgeon. <i>JAMA Surgery</i> , 2017, 152, 410.	2.2	32
35	Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2022, 5, 113-117.	2.6	30
36	Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma. <i>Annals of Nuclear Medicine</i> , 2018, 32, 69-74.	1.2	28

#	ARTICLE	IF	CITATIONS
37	Activation and Proliferation of PD-1+ Kidney Double-Negative T Cells Is Dependent on Nonclassical MHC Proteins and IL-2. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 277-292.	3.0	27
38	Radiotherapy for stage I and II testicular seminomas: Secondary malignancies and survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 606.e1-606.e7.	0.8	26
39	Effect of a prospective opioid reduction intervention on opioid prescribing and use after radical prostatectomy: results of the Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery (ORIOLES) Initiative. <i>BJU International</i> , 2020, 125, 426-432.	1.3	26
40	Renal Mass Biopsy is Associated with Reduction in Surgery for Early-Stage Kidney Cancer. <i>Urology</i> , 2020, 135, 76-81.	0.5	25
41	Extent of renal vein invasion influences prognosis in patients with renal cell carcinoma. <i>BJU International</i> , 2016, 118, 112-117.	1.3	24
42	Evidence-based quality and accuracy of YouTube videos about nephrolithiasis. <i>BJU International</i> , 2021, 127, 247-253.	1.3	23
43	Comprehensive profile of GATA binding protein 3 immunohistochemical expression in primary and metastatic renal neoplasms. <i>Human Pathology</i> , 2014, 45, 244-248.	1.1	22
44	Defining the Role of Intraoperative Transesophageal Echocardiography During Radical Nephrectomy With Inferior Vena Cava Tumor Thrombectomy for Renal Cell Carcinoma. <i>Urology</i> , 2017, 107, 161-165.	0.5	22
45	Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. <i>European Urology</i> , 2020, 78, 360-368.	0.9	22
46	Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance. <i>Journal of Urology</i> , 2021, 205, 1069-1074.	0.2	21
47	Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. <i>Oncotarget</i> , 2017, 8, 104182-104192.	0.8	20
48	Comparison of Perioperative and Pathologic Outcomes Between Single-port and Standard Robot-assisted Radical Prostatectomy: An Analysis of a High-volume Center and the Pooled World Experience. <i>Urology</i> , 2021, 147, 223-229.	0.5	20
49	Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e515-e520.	0.9	19
50	Frontiers in robot-assisted retroperitoneal oncological surgery. <i>Nature Reviews Urology</i> , 2017, 14, 731-741.	1.9	19
51	Variability of interobserver agreement on feasibility of partial nephrectomy before and after neoadjuvant axitinib for locally advanced renal cell carcinoma (<sc>RCC</sc>): independent analysis from a phase <sc>II</sc> trial. <i>BJU International</i> , 2016, 117, 629-635.	1.3	18
52	Surgical removal of renal tumors with low metastatic potential based on clinical radiographic size: A systematic review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 519-524.	0.8	18
53	Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4518-4518.	0.8	18
54	The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas. <i>European Urology Focus</i> , 2017, 3, 584-589.	1.6	17

#	ARTICLE	IF	CITATIONS
55	Use of quantitative SPECT/CT reconstruction in ^{99m} Tc-sestamibi imaging of patients with renal masses. <i>Annals of Nuclear Medicine</i> , 2018, 32, 87-93.	1.2	17
56	In-office Transperineal Prostate Biopsy Using Biplanar Ultrasound Guidance: A Step-by-Step Guide. <i>Urology</i> , 2019, 133, 247.	0.5	17
57	Surgical Management of Advanced Kidney Cancer: The Role of Cytoreductive Nephrectomy and Lymphadenectomy. <i>Journal of Clinical Oncology</i> , 2018, 36, 3601-3607.	0.8	16
58	Cost-effectiveness Analysis of ^{99m} Tc-sestamibi SPECT/CT to Guide Management of Small Renal Masses. <i>European Urology Focus</i> , 2021, 7, 827-834.	1.6	16
59	^{99m} Tc-sestamibi SPECT/CT for the characterization of renal masses: a pictorial guide. <i>British Journal of Radiology</i> , 2018, 91, 20170526.	1.0	15
60	Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomes. <i>World Journal of Urology</i> , 2018, 36, 73-78.	1.2	15
61	Stage-specific conditional survival in renal cell carcinoma after nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 6.e1-6.e7.	0.8	15
62	Selecting Patients with Small Renal Masses for Active Surveillance: A Domain Based Score from a Prospective Cohort Study. <i>Journal of Urology</i> , 2019, 201, 886-892.	0.2	15
63	Primary and post-chemotherapy robotic retroperitoneal lymph node dissection for testicular cancer: a review. <i>Translational Andrology and Urology</i> , 2020, 9, 949-958.	0.6	15
64	Multiple growth periods predict unfavourable pathology in patients with small renal masses. <i>BJU International</i> , 2018, 121, 732-736.	1.3	14
65	Can preoperative renal mass biopsy change clinical practice and reduce surgical intervention for small renal masses?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 735.e17-735.e23.	0.8	14
66	Nuclear imaging of renal tumours: a step towards improved risk stratification. <i>Nature Reviews Urology</i> , 2015, 12, 445-450.	1.9	13
67	Partial Nephrectomy for the Treatment of Translocation Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e199-e201.	0.9	13
68	Safety and Feasibility of Direct Magnetic Resonance Imaging-guided Transperineal Prostate Biopsy Using a Novel Magnetic Resonance Imaging-safe Robotic Device. <i>Urology</i> , 2017, 109, 216-221.	0.5	13
69	Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS5099-TPS5099.	0.8	13
70	Recent advances in immunotherapy for kidney cancer. <i>Discovery Medicine</i> , 2016, 21, 305-13.	0.5	13
71	Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5077-5077.	0.8	12
72	The natural history of renal functional decline in patients undergoing surveillance in the DISSRM registry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 166.e17-166.e20.	0.8	11

#	ARTICLE	IF	CITATIONS
73	Photorealistic 3-Dimensional Cinematic Rendering of Clear Cell Renal Cell Carcinoma From Volumetric Computed Tomography Data. <i>Urology</i> , 2018, 115, e3-e5.	0.5	11
74	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS684-TPS684.	0.8	11
75	Instrument Life for Robot-assisted Laparoscopic Radical Prostatectomy and Partial Nephrectomy: Are Ten Lives for Most Instruments Justified?. <i>Urology</i> , 2015, 86, 942-946.	0.5	10
76	Robotic Primary RPLND for Stage I Testicular Cancer: a Review of Indications and Outcomes. <i>Current Urology Reports</i> , 2016, 17, 41.	1.0	10
77	Characterization of indeterminate renal masses with molecular imaging: how do we turn potential into reality?. <i>EJNMMI Research</i> , 2017, 7, 34.	1.1	10
78	Clinical, pathologic, and genomic profiles of exceptional responders to anti-PD1 therapy in renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 625-625.	0.8	9
79	Robot-Assisted Adrenalectomy (Total, Partial, & Metastasectomy). <i>Urologic Clinics of North America</i> , 2014, 41, 539-547.	0.8	8
80	Downgrading of grade group 2 intermediate-risk prostate cancer from biopsy to radical prostatectomy: Comparison of outcomes and predictors to identify potential candidates for active surveillance. <i>Cancer</i> , 2020, 126, 1632-1639.	2.0	8
81	Stereotactic Ablative Radiotherapy for the Treatment of Clinically Localized Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2015, 2015, 1-6.	0.6	7
82	Active Surveillance for Small Renal Masses: A Review of the Aims and Preliminary Results of the DISSRM Registry. <i>Current Urology Reports</i> , 2016, 17, 4.	1.0	7
83	Evidence-based analysis of online consumer information about prostate artery embolization for benign prostatic hyperplasia. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 106-113.	2.0	7
84	Primary robotic retroperitoneal lymph node dissection following orchiectomy for testicular germ cell tumors: a single-surgeon experience. <i>Journal of Robotic Surgery</i> , 2021, 15, 309-313.	1.0	7
85	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4596-TPS4596.	0.8	7
86	Intermediate-term outcomes from the DISSRM registry: A prospective analysis of active surveillance in patients with small renal masses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 430-430.	0.8	7
87	Spontaneous Regression of a Low-Grade Renal Cell Carcinoma With Oncocytic Features After Renal Mass Biopsy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1083-e1085.	0.9	6
88	Intraoperative Nerve Monitoring in Robotic-Assisted Resection Of Presacral Ganglioneuroma: Operative Technique. <i>Operative Neurosurgery</i> , 2019, 16, 103-110.	0.4	6
89	Adjuvant Therapy for Urothelial and Renal Cell Carcinoma. <i>European Urology Focus</i> , 2020, 6, 3-6.	1.6	6
90	Complications after open and robot-assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial. <i>BJU International</i> , 2021, 127, 190-197.	1.3	6

#	ARTICLE	IF	CITATIONS
91	Outcomes of partial nephrectomy in patients who meet percutaneous ablation criteria. Central European Journal of Urology, 2015, 68, 132-6.	0.2	6
92	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. Medical Oncology, 2022, 39, 63.	1.2	6
93	Active Surveillance Versus Immediate Intervention for Small Renal Masses: A Cost-Effectiveness and Clinical Decision Analysis. Journal of Urology, 0, , .	0.2	6
94	Angiomyolipoma with epithelial cysts: Add one to the differential of cystic renal lesions. International Journal of Urology, 2015, 22, 1081-1082.	0.5	5
95	Use of 99m Tc-sestamibi Single-photon Emission Computed Tomography / X-ray Computed Tomography in the Diagnosis of Hybrid Oncocytic / Chromophobe Tumor in a Pediatric Patient. Urology, 2018, 113, 206-208.	0.5	5
96	Incidental periprostatic schwannoma discovered during evaluation for prostatic adenocarcinoma. Urology Case Reports, 2020, 31, 101150.	0.1	5
97	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2021, 39, TPS4596-TPS4596.	0.8	5
98	Local and Regional Recurrences of Clinically Localized Renal Cell Carcinoma after Nephrectomy: A 15 Year Institutional Experience with Prognostic Features and Oncologic Outcomes. Urology, 2021, 154, 201-207.	0.5	5
99	Splitting One Kidney into Two: Robotic Partial Kidney Transplant in a Porcine Model. European Urology, 2016, 69, 968-969.	0.9	4
100	Cost-effectiveness Analysis of Nonâ€“risk-adapted Active Surveillance for Postorchiectomy Management of Clinical Stage I Seminoma. European Urology Focus, 2020, 7, 1409-1417.	1.6	4
101	Patient and in-hospital predictors of post-discharge opioid utilization: Individualizing prescribing after radical prostatectomy based on the ORIOLES initiative. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 104.e9-104.e15.	0.8	4
102	A prospective comparative study of routine versus deferred pelvic drain placement after radical prostatectomy: impact on complications and opioid use. World Journal of Urology, 2021, 39, 1845-1851.	1.2	3
103	Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial. Journal of Urology, 2021, 205, 1681-1688.	0.2	3
104	Freehand Transperineal Prostate Biopsy with Three-Dimensional Ultrasound Organ-Based Tracking. Journal of Endourology, 2021, 35, S-7-S-16.	1.1	3
105	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2019, 37, TPS4597-TPS4597.	0.8	3
106	Selfâ€“reported quality of life as a predictor of mortality in renal cell carcinoma. Cancer, 2022, 128, 479-486.	2.0	3
107	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2020, 38, TPS5101-TPS5101.	0.8	3
108	Robotic adrenalectomy: the jury is still out. Gland Surgery, 2015, 4, 277-8.	0.5	3

#	ARTICLE	IF	CITATIONS
109	Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives.. Journal of Clinical Oncology, 2022, 40, 5015-5015.	0.8	3
110	Renal Pseudoaneurysm Mimicking Local Cancer Recurrence After Partial Nephrectomy. Urology Case Reports, 2017, 11, 1-3.	0.1	2
111	Margin Assessment in Renal Surgery Using a Handheld Optical Coherence Tomography Probe. Urology, 2018, 113, 241-245.	0.5	2
112	Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [¹¹¹ In]In- ⁶⁷ Cu-XYMSR-01 for phase I regulatory approval. Journal of Labelled Compounds and Radiopharmaceuticals, 2021, 64, 243-250.	0.5	2
113	Management of Metachronous Bilateral Testis Cancer in a Patient with Pre-B Cell ALL. Case Reports in Urology, 2015, 2015, 1-4.	0.1	1
114	Incidentally Detected ¹⁸ F-FDG-Avid Prostate Cancer Diagnosed Using a Novel Fusion Biopsy Platform. Journal of Endourology Case Reports, 2019, 5, 68-70.	0.3	1
115	Erythropoietin to Enhance Recovery of Erectile Function in Men Following Radical Prostatectomy: The ERECT Trial. European Urology Focus, 2019, 5, 698-699.	1.6	1
116	Volume-outcome relationships for kidney cancer may be driven by disparities and patient risk. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 439.e1-439.e8.	0.8	1
117	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. Journal of Clinical Oncology, 2018, 36, TPS710-TPS710.	0.8	1
118	Reply to Valerian Ciprian Lucan, Salvatore Buttici, Rosa Pappalardo, Carlo Magno's Letter to the Editor re: Mark W. Ball, Nathaniel Readal, Phillip M. Pierorazio, Mohamad E. Allaf. Splitting One Kidney into Two: Robotic Partial Kidney Transplant in a Porcine Model. Eur Urol 2016;69:968-9. European Urology, 2016, 70, e82.	0.9	0
119	Reproducibility of Cold Uptake Radiomics in ^{99m} Tc-Sestamibi SPECT Imaging of Renal Cell Carcinoma. , 2017, , .		0
120	Detection of a Meckel's diverticulum on PSMA PET/CT: A case report. Urology Case Reports, 2020, 33, 101306.	0.1	0
121	4540 THE IMPACT OF SURGEON AND HOSPITAL VOLUME ON 30-DAY OUTCOMES AND COST FOR RENAL CANCER SURGERY. Journal of Clinical and Translational Science, 2020, 4, 148-148.	0.3	0
122	Re: Robert J. Motzer, Paul Russo, Naomi Haas, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol 2021;79:334-8. European Urology, 2021, 80, e33-e34.	0.9	0
123	Study of PSMA-targeted ¹⁸ F-DCFPyL PET/CT in the evaluation of men with an elevated PSA following radical prostatectomy.. Journal of Clinical Oncology, 2016, 34, 299-299.	0.8	0
124	Incidence of T3a upstaging and survival after partial nephrectomy: Size-stratified rates and implications for prognosis.. Journal of Clinical Oncology, 2017, 35, 4588-4588.	0.8	0
125	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2018, 36, TPS4597-TPS4597.	0.8	0
126	Deep learning algorithm improves identification of men with low-risk prostate cancer using PSMA-targeted ^{99m} Tc-MIP-1404 SPECT/CT.. Journal of Clinical Oncology, 2019, 37, e16572-e16572.	0.8	0